trending Market Intelligence /marketintelligence/en/news-insights/trending/BwXglQhZiPoxbgSfzkFUag2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Shield Therapeutics licenses iron deficiency drug to Beijing Aosaikang

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Shield Therapeutics licenses iron deficiency drug to Beijing Aosaikang

U.K.'s Shield Therapeutics PLC sold the rights to its iron deficiency treatment Feraccru in parts of Asia for an up front payment of $11.4 million.

China's Beijing Aosaikang Pharmaceutical Co. Ltd. entered an agreement with Shield Therapeutics to commercialize the drug in the country, as well as in Hong Kong, Macau and Taiwan. In addition to the up front payment, Beijing Aosaikang agreed to pay up to a further $51.4 million if the drug achieves certain milestones, including $11.4 million once the medicine is approved in China.

Shield Therapeutics will also receive 10% to 15% royalties on net sales of Feraccru, which is known as Accrufer in the U.S.

Feraccru is already approved in the European Union to treat iron deficiency in adults and in Switzerland for treating iron deficiency anemia in adults with inflammatory bowel disease. The medicine is a non-salt, oral formulation of ferric iron, seen as a safer alternative to intravenous iron therapy.

The drug is also approved in the U.S.